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Abstract
Background: In recent years it has become clear that fetal anomalies can already be detected at the end of the
first trimester of pregnancy by two-dimensional (2D) ultrasound. This is why increasingly in developed countries the
first trimester anomaly scan is being offered as part of standard care. We have developed a Virtual Reality (VR)
approach to improve the diagnostic abilities of 2D ultrasound. Three-dimensional (3D) ultrasound datasets are used
in VR assessment, enabling real depth perception and unique interaction. The aim of this study is to investigate
whether first trimester 3D VR ultrasound is of additional value in terms of diagnostic accuracy for the detection of
fetal anomalies. Health-related quality of life, cost-effectiveness and also the perspective of both patient and
ultrasonographer on the 3D VR modality will be studied.
Methods: Women in the first trimester of a high risk pregnancy for a fetus with a congenital anomaly are eligible
for inclusion. This is a randomized controlled trial with two intervention arms. The control group receives ‘care as
usual’: a second trimester 2D advanced ultrasound examination. The intervention group will undergo an additional
first trimester 2D and 3D VR ultrasound examination. Following each examination participants will fill in validated
questionnaires evaluating their quality of life and healthcare related expenses. Participants’ and ultrasonographers’
perspectives on the 3D VR ultrasound will be surveyed. The primary outcome will be the detection of fetal
anomalies. The additional first trimester 3D VR ultrasound examination will be compared to ‘care as usual’. Neonatal
or histopathological examinations are considered the gold standard for the detection of congenital anomalies. To
reach statistical significance and 80% power with a detection rate of 65% for second trimester ultrasound
examination and 70% for the combined detection of first trimester 3D VR and second trimester ultrasound
examination, a sample size of 2800 participants is needed.
Discussion: First trimester 3D VR detection of fetal anomalies may improve patients’ quality of life through
reassurance or earlier identification of malformations. Results of this study will provide policymakers and healthcare
professionals with the highest level of evidence for cost-effectiveness of first trimester ultrasound using a 3D VR
approach.
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Background
Congenital anomalies account for 15–20% of all fetal
deaths and nearly 25% of all neonatal deaths in Europe
[1]. Around 2% of all pregnancies are affected by a major
anomaly that requires extensive postnatal support [2]. A
correct prenatal diagnosis can direct future parents to
the best possible care.
According to international and Dutch national
guidelines, all pregnant women are offered a second tri-
mester two-dimensional (2D) ultrasound scan to screen
for fetal anomalies [3–5]. Subsequently, future parents
are counseled about the possible diagnosis, prognosis
and treatment. However, by the end of the first trimes-
ter (< 14 weeks gestational age (GA)), a considerable
amount of fetal anomalies can already be detected
using 2D ultrasound [6, 7]. A systematic review, per-
formed in a high risk population, showed that 61% of
the (detectable) anomalies can already be identified by
a first trimester anomaly scan [6]. A more recent pro-
spective cohort study performed in The Netherlands
even found a detection rate of 63% within a low risk
population, which demonstrates the importance of per-
forming a first trimester anomaly scan [8]. The ob-
served high detection rate of major anomalies and
ultrasonographic markers coincides with other advan-
tages. Firstly, detection of an anomaly at an early stage
in pregnancy provides additional time for counseling,
advanced genetic testing, parental thought and reflec-
tion [9]. Secondly, a first trimester scan showing no ab-
normalities might provide parental reassurance,
especially in a population at higher risk of fetal anomal-
ies. Thirdly, if applicable, an early termination of preg-
nancy is considered a low risk procedure, in contrast to
termination during advanced gestation, which shows a
greater risk of maternal morbidity and mortality [10,
11]. When pregnant women opt for an early termin-
ation of pregnancy, methods available are considered
less invasive when compared to termination at an ad-
vanced stage. Moreover, it has been shown that termin-
ation of pregnancy at a more advanced gestational age
is associated with an increased risk of an adverse psy-
chological outcome [12].
Finally, women with an increased BMI (i.e. > 30 kg/m2)
could profit from a first trimester anomaly scan. It is
known that the performance of the second trimester
transabdominal ultrasound examination in women with
an increased BMI is limited with regards to detection
and completeness [13]. Incomplete ultrasound examin-
ation may lead to suboptimal care for these women. The
efforts and costs greater when compared to women with
a BMI < 30 kg/m2. In the first trimester, transvaginal
ultrasound may be used to overcome limited visibility in
the women with an increased BMI.
From the above mentioned, we can conclude that
postponing detection of anomalies to the second
trimester of pregnancy can be regarded as a missed
opportunity. This is the most compelling argument
mentioned in international guidelines proposing a first
trimester anomaly scan to be offered to all women,
accompanied by adequate counseling of the potential
benefits and limitations [14]. However, there is a lack
of implementation of the guidelines’ advice in nation-
wide screening programs. The available literature con-
cerning detection rates and feasibility of the first
trimester anomaly scan include a low risk population
and are retrospective in design [6]. Prospective or
randomized trials for a high risk population are lim-
ited in number. In spite of this, some countries are
offering a first trimester anomaly scan to their popu-
lation [15].
Over the years several factors have contributed to the
quality of first trimester 2D ultrasound imaging. The
most important ones are the introduction of high fre-
quency ultrasound probes and using the transvaginal ap-
proach. The addition of an application providing three-
dimensional (3D) renderings have further enhanced first
trimester ultrasound imaging by enabling improved
visualization of fetal structures [16]. However, there are
also limitations concerning 3D ultrasound examinations.
The 3D datasets are presented as 3D reconstructions on
2D screens. Therefore, the third dimension, depth, can-
not be used to its fullest since the images are being pre-
sented on 2D media. Improved visualization can be
reached using Virtual Reality (VR) displays. VR enables
true depth perception and provides 3D interaction. ‘Ho-
lograms’ of the 3D ultrasound scans can be created using
the V-Scope software (Erasmus MC, Rotterdam, The
Netherlands), allowing presentation of volumetric data
in the best possible way [17, 18]. Following the acquisi-
tion of 3D data, using any 3D probe, application of V-
scope imaging software enables 3D data to be displayed
as ‘holograms’ on a 3D display, generating depth percep-
tion using 3D glasses. The difference between 2D, 3D
and 3D VR is depicted in Fig. 1. These generated
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‘holograms’, show easier to interpret images and provide
detailed and relevant information about the fetal anat-
omy [19]. 3D VR might improve antenatal counseling of
future parents.
The VR technology has already been used extensively
to visualize 3D ultrasound datasets in the Barco I-Space
system; which is a special room enabling VR [16]. To
facilitate clinical use, a 3D VR Desktop system has been
developed (Fig. 2 – photo published with consent of
future parents and examiner). This system can be used
in daily outpatient practice, offering the same functional-
ity at a fraction of the cost [17, 18]. Baken et al. have
compared 2D ultrasound, 3D ultrasound and 3D VR for
detection of first trimester fetal anomalies [20]. This
retrospective study showed that the general diagnostic
performance between the different methods was com-
parable (sensitivity 3D: 52.2%, 3D VR 62.6%; specificity
3D: 99.7%, 3D VR 99.6%). 3D VR has shown to be of
additional value in the detection of anomalies, especially
with regards to limb defects, conjoined twins and aneu-
ploidy [21, 22]. Besides improving visualization, V-Scope
enables the measurement of regularly used biometric
features (e.g. crown-rump length) and more recently
developed biometric and volumetric features (e.g. em-
bryonic volume) with high reproducibility [23–27].
There is no difference with regards to the measure-
ments performed in the I-Space or 3D VR Desktop
system (excellent inter- and intra-observer class cor-
relation (> 0.99)) [18].
In addition to the introduction of a first trimester
anomaly scan in a high risk population, the use of VR as
an additional technique is the subject of the current
study. The diagnostic yield of the 3D VR will be com-
pared with international guidelines and literature.
Fig. 1 Different imaging techniques of the same pregnancy in the first trimester. Images, representing respectively transvaginal two-dimensional
(panel a), three-dimensional (panel b) and three-dimensional virtual reality (Panel c) ultrasound images of the same pregnancy in the
first trimester
Fig. 2 The 3D VR Desktop system in the outpatient clinic. The examiner explains the anatomical landmarks of the fetus at 13 weeks’ GA to the
future parents on the Virtual Reality (VR) system. All are wearing glasses and the examiner is interacting by means of the virtual pointer. Due to
privacy regulations, the examiner and future parents are not depicted in this photo. The photo was used for publication with consent of
examiner and future parents
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Preferably, before implementing a new modality in daily
clinical practice, cost-effectiveness should be considered
[28]. Cost-effectiveness may be studied from several per-
spectives [29]. Ideally, this includes the societal perspec-
tive on medical costs, comprising both the direct (i.e.
expenses associated with the disease and its complica-
tions) and indirect costs (e.g. effect of the illness for the
patient on society, such as productivity loss). Therefore,
we designed a randomized controlled trial to study the
cost-effectiveness of the first trimester 3D VR ultrasound
in a high risk population. Cost-effectiveness will be ex-
plored in terms of health-related quality of life and costs
from a societal perspective. Also, the perspective of both
patient and ultrasonographer on the new 3D VR modal-
ity will be surveyed.
Methods/design
Primary study objective
The general aim is to study the detection rate of a first
trimester anomaly scan using 3D VR ultrasound in
addition to the second trimester 2D ultrasound examin-
ation in a high risk population.
Secondary study objectives
Additionally, we will investigate quality of life as
reflected by psychological burden, and cost-effectiveness
of the first trimester 3D VR ultrasound. Both factors will
be compared between the intervention and control
group. Finally, patient and ultrasonographer perspectives
will be studied.
Study design (see Fig. 3)
The design is a randomized controlled trial amongst
women with a high risk for fetal anomalies in their preg-
nancy. Participants will be allocated to either the control
or intervention group. In the control group, participants
will receive ‘care as usual’ according to the Dutch na-
tional guidelines. The intervention group will undergo
an additional first trimester 2D and 3D VR ultrasound
examination. Both groups will be asked to complete
questionnaires on wellbeing, quality of life, stress, anx-
iety and medical costs.
Study population
Women with an increased risk of carrying a fetus with a
congenital anomaly (i.e. high risk) are eligible for partici-
pation. Women are considered high risk when: they have
a previous child with an anomaly or one of the future
parents has an anomaly, there is a second or third de-
gree family member (of the fetus) with a neural tube de-
fect, there is a maternal disease (such as diabetes or
auto-immune disease), the pregnancy is conceived after
IntraCytoplasmic Sperm Injection (ICSI), following
teratogenic maternal medication or substance use or
when there is a monochorionic twin pregnancy.
They have to meet the following additional criteria:
– 18 years of age and older
– Within the first trimester of pregnancy, up to 14 + 0
weeks’ gestation
– Singleton or twin pregnancy
– Sufficient understanding of the Dutch language
Excluded from participation are women with a non-
viable pregnancy and an anomaly detected before
randomization.
Procedures, recruitment and randomization
Eligible women will be identified by the participating
hospital. Referring healthcare providers will be con-
tacted to ensure timely referral (< 14 + 0 weeks’ GA).
Women eligible for the trial will be counseled before
participation by medical doctors or research nurses in
accordance to the ‘Good Clinical Practice (GCP)’
guidelines [30]. Written informed consent will be ob-
tained (Supplement 1 and 2).
Fig. 3 Flow chart depicting the design of the VR FETUS Study. Flowchart showing the study design of the study; including the inclusion criteria,
the usual care, the intervention arm, the control arm and the follow-up. GA: Gestational Age. 2D: two dimensional. US: Ultrasound. 3D:
three dimensional
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Following participation, the participant will be entered
in a web-based computerized database (ALEA®) for
randomization. After complete registration in the online
randomization database, the allocation will be shown.
The online randomization software is available at all
times. Randomization will be performed using block
randomization with random block samples of N = 4–16.
Due to the nature of the intervention, this will not be a
blinded study.
Control group
In the control group, participants will receive ‘care as
usual’ which consists of a viability and pregnancy dating
ultrasound examination around 10 weeks’ gestation
followed by counseling for aneuploidy testing. Aneu-
ploidy testing will be performed either via the first tri-
mester combined test or via non-invasive prenatal
testing (NIPT). Furthermore, an advanced ultrasound
examination between 18 and 22 weeks’ gestation will be
performed to screen for fetal anomalies. When indicated,
additional ultrasound examinations will be planned, for
instance fetal cardiac evaluation with a pediatric
cardiologist.
Intervention group
The intervention consists of a first trimester 2D and 3D
VR ultrasound examination between 11 and 14 weeks
GA. The examination will be performed on a Voluson
E10 (GE Healthcare, Austria) using a 4–9MHz or 6–13
MHz high frequency transvaginal transducer or 2–6
MHz transabdominal transducer. A complete ultrasound
examination will take 30–45 min per fetus. Ultrasound
examinations will be performed according to inter-
national guidelines on safe use of ultrasound in the first
trimester of pregnancy and as such, total scanning time
will be kept as low as possible (ALARA-principle) [31].
The ultrasound examination will be performed by two
examiners (examiner A and B) unable to see of each
other’s results. Examiner A will perform the 2D ultra-
sound and (2D) evaluation of fetal organ structures
using a protocol with standard anatomical views and
measurements (Supplement 3). The cardiac examination,
based on international ISUOG practice guidelines, is ex-
panded with at least 7 measurements or planes: four
chamber view with and without color Doppler, left out-
flow tract with color Doppler, right outflow tract with
color Doppler, three vessel view, trachea view, tricuspid
valve pulsed wave Doppler and a measurement of car-
diac axis [32]. By default a transvaginal ultrasound
examination will be performed. Only if fetal structures
cannot be sufficiently visualized or if a women objects to
a transvaginal examination, a transabdominal approach
will be performed. During the 2D ultrasound examin-
ation, in addition to the already described 3D ultrasound
datasets, four-dimensional spatio-temporal image correl-
ation (4D STIC) datasets of the fetal heart will be
acquired. Examiner B will evaluate the acquired 3D vol-
umes using the 3D VR Desktop system [18]. Participants
undergoing the first trimester scan will be unable to see
the 2D scan. This is necessary to test their experience
and objective reaction with respect to the 3D VR images.
Thus, the influence of 3D VR ‘holograms’ on future
parents’ perception can be investigated and compared
to their 2D ultrasound experience later in pregnancy
(at 20 weeks).
The 3D VR images will be extensively discussed with
the future parents: this will take 30min. At the end of
the 3D VR evaluation and discussion, examiners A and
B will compare their findings to reach agreement. In
case of an anomaly, participants will be informed about
the presence or suspicion of malformations by examiner
B. Routine care will then be offered, consisting of an ad-
vanced anomaly scan by an experienced and independ-
ent sonographer.
In the absence of an anomaly, the intervention group
will undergo a routine second trimester 2D ultrasound
scan as part of ‘care as usual’.
Virtual reality examination
The 3D VR Desktop provides a user-friendly possibility
to interact with the ‘hologram’ and measure distances
and semi-automatic volumes of different structures [16].
The desktop is equipped with a wireless joystick to ma-
nipulate the 3D volumes. A ‘hologram’ of the 3D volume
is created using the V-Scope software (Erasmus MC,
Rotterdam, The Netherlands). With stereoscopic glasses
(similar to those used to watch a 3D movie) the
examiners and patients (i.e. future parents) are able to
perceive depth and to interact with the volume in all
three dimensions. The ideal viewing angle or cutting
plane can be obtained by turning, enlarging and clipping
the 3D volume. The 3D VR examination will be per-
formed using the same protocol with standard anatom-
ical views and measurements (Supplement 3).
Questionnaires
All participants will fill out questionnaires on health re-
lated quality of life. The following validated question-
naires will be sent at fixed time points in pregnancy: the
MOS 36-item Short Form Health Survey (SF-36), the
Hospital Anxiety and Depression Scale (HADS), the
Spielberger State-Trait Anxiety Inventory (STAI) and a
visual analogue scale (VAS) for wellbeing [33–35]. The
four questionnaires will be sent digitally to the partici-
pants on the day of inclusion, the first trimester 3D VR
ultrasound (or after 13 weeks GA for the control group),
the second trimester 2D ultrasound and 4 weeks after
the estimated due date, respectively. The answers will be
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recorded on a secure webserver on the Erasmus MC
premises.
Direct healthcare costs will be recorded using the
iMTA Medical Consumption Questionnaire (iMTA
MCQ) [36]. All significant costs and health effects on
the short term up to 4–6 weeks after delivery or termin-
ation of pregnancy will be considered. Therefore, these
questionnaires will be sent at 20 and 32 weeks GA and
4 weeks after the estimated due date. In case of an intra-
uterine fetal demise or termination of pregnancy during
the trial, women will be sent specifically adjusted
questionnaires.
Participant perspective on the 3D VR ultrasound will
be evaluated with an in-house developed questionnaire.
This survey includes questions about the value of ultra-
sound imaging in the first trimester and personal
perception of the added value of 3D VR. This question-
naire will be sent after the first trimester 3D VR ultra-
sound or around 13 weeks GA in the control group.
This questionnaire will be validated in a subset of 50
participants.
Ultrasonographer opinion of both the first trimester
2D and the 3D VR ultrasound will be evaluated by an-
other in-house developed questionnaire. More specific-
ally, the additional value of the 3D VR in terms of
patient understanding, counseling and detection of
anomalies will be examined.
Follow-up
Baseline characteristics will be extracted from the elec-
tronic medical records and stored in a secured database.
Only a select group of staff will have access to partici-
pant characteristics to ensure patient confidentiality.
Hospital or midwifery charts will be obtained to
complete follow-up on neonates. In case of a fetal anom-
aly, additional information will be obtained, such as gen-
etic testing or autopsy results.
Outcome measurements
The primary outcome will be the detection rate of fetal
anomalies using first trimester 3D VR ultrasound in
addition to the second trimester 2D ultrasound in a high
risk population. Neonatal or histopathological examina-
tions are considered the gold standard for the detection
of congenital anomalies. For the detection rate analysis
the sensitivity, specificity, positive and negative predict-
ive values will be calculated for all ultrasound techniques
for first trimester examination (i.e. 2D and 3D VR) in
the intervention group and second trimester 2D examin-
ation in both groups (control group as well as interven-
tion group). The detection rate of both first trimester
examinations (i.e. 2D and 3D VR) will be compared. The
detection rate of first trimester 2D will also be compared
to the second trimester 2D ultrasound in the
intervention group. In addition, we will assess the per-
formance of the first trimester anomaly 2D and 3D VR
ultrasound and the additional findings of the subsequent
second trimester 2D ultrasound to gain a better insight
into the whole diagnostic process.
The diagnostic performance of the first trimester ultra-
sound examination protocol will be compared to inter-
national ultrasound guidelines. Anatomical views (i.e.
sagittal, transversal) according to our standardized
protocol acquired per fetal structure will be evaluated as
satisfactory or unsatisfactory. This assessment will be
used to evaluate image quality per fetal structure and
per modality, i.e. first trimester 2D and 3D VR. By doing
this we will be able to examine the anatomical views
which are essential to be included in the protocol, and
the ones which are not. This evaluation will lead to
optimization of the examination protocol in the future.
Secondary outcome measures will be health-related
quality of life and cost-effectiveness of first trimester 3D
VR ultrasound from a societal perspective. Health
related quality of life will be expressed in physical, emo-
tional and social functioning. Quality Adjusted Life
Years (QALY’s) will be calculated from a maternal
perspective, derived from the validated questionnaires.
Actual expenses during the study will be measured using
the standard costs as stated by the Dutch costing guide-
lines [37]. For each strategy (control versus intervention)
the quality of life will be computed as well as the average
costs per patient. The incremental cost-effectiveness ra-
tio (ICER) will be calculated by dividing the difference in
costs by the difference in quality of life. It represents the
extra costs required to obtain one QALY. Furthermore,
the cost per anomaly detected will be estimated. The
cost-effectiveness analysis will span a period from ap-
proximately 8 weeks of gestation, when regular obstetric
care starts, up to approximately 2 months beyond the es-
timated date of delivery. In this analysis, costs and effects
will not be discounted due to a short time frame. Indir-
ect costs will not be accounted for. The costs will be
presented in Euros. The index year will be 2018.
Additionally, through a newly implemented question-
naire, the perspective of both patient and ultrasonogra-
phers on the new 3D VR modality will be surveyed. The
participant perspective of the first trimester 3D VR
ultrasound group (=intervention) will be compared to
second trimester 2D ultrasound (=control).
An overview of all patients’ characteristics and data is
shown in Table 1.
Quality
Sonographers will be trained to perform first trimester
3D VR ultrasound scans. As the first trimester ultra-
sound scan for fetal anomalies is currently not part of
standard care in the Netherlands, the sonographers will
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Table 1 Patient characteristics collected within the VR FETUS study. Details of data collection form the first trimester up to 6 weeks
after delivery are depicted
Maternal Characteristics Outcome
Age Years (mean ± SD)
Ethnicity Dutch/Other western/Non-western
Level of education Low, middle, high
Postal code
Medical history Unremarkable/Diabetes/Epilepsy/Other
Obstetrical history Parity, miscarriage, previous pregnancy with congenital anomaly
Family history Unremarkable/family members with congenital anomaly
Marital status Married/not married
Global household income €0–20.000/€20.000–35.000/€35.000–65.000/>€65.000 annually
BMI Kg/m2 (mean ± SD)
Alcohol use during first trimester No/Yes: how many units per day?
Smoking during first trimester No/yes: how many cigarettes per day
Recreational drug use during first trimester No/yes: what drugs; frequency per day?
Folic acid use during and/or prior to pregnancy No/yes during pregnancy/yes started prior to pregnancy
Pregnant after artificial reproductive technology No/yes: what type of assisted reproduction
First trimester screening for aneuploidy No/yes: result
Medication No/yes: what medication, dosage, starting and stopping date?
Antidepressant Never/yes currently/yes previous use
Questionnaires Timing
Current health statusa At inclusion, intervention or 13 weeks’ GA, 20 weeks’ GA, 6 weeks after due date
Anxiety and depressionb At inclusion, intervention or 13 weeks’ GA, 20 weeks’ GA, 6 weeks after due date
State and trait anxietyc At inclusion, intervention or 13 weeks’ GA, 20 weeks’ GA, 6 weeks after due date
Current health status by VASd At inclusion, intervention or 13 weeks’ GA, 20 weeks’ GA, 6 weeks after due date
Medical consumptione At 20 weeks’ GA, 32 weeks’ GA, 6 weeks after due date
Patient satisfaction with 3D VR At intervention or 13 weeks’ GA, 6 weeks after due date
Ultrasound Measurements
At inclusion, 1st trimester Viability, CRL, multiple pregnancies, location
Intervention: 2D + 3D VR First Trimester Ultrasound,
1st trimester
Fetal anomaly scan using 2D and 3D VR. Growth parameters, detection of anomaly.
See supplement A
Advanced fetal anomaly scan, 2nd trimester Fetal anomaly scan using 2D. Growth parameters, detection of anomaly
Pregnancy outcome Outcome
Outcome Live birth, termination, intra-uterine fetal demise
Mode of delivery Vaginal / Instrumental delivery / Cesarean section
Gestational age at delivery Days (mean ± SD)
Invasive testing No/yes: result
Date of invasive testing
Neonatal outcome Outcome
Birthweight Birthweight, grams (mean ± SD)
Gender Male/female
Congenital malformation No/yes: what malformation
Prenatal diagnosis Confirmed/discrepancy in findings: postnatal new or other findings
aSF-36: MOS 36-item Short Form Health Survey, bHADS: Hospital Anxiety and Depression Scale, cSTAI: Spielberger State-Trait Anxiety Inventory, dVAS: visual
analogue scale, eiMTA MCQ: iMTA Medical Consumption Questionnaire, CRL: Crown-Rump Length, 2D: two-dimensional, 3D VR: three-dimensional virtual reality
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receive additional training. They will all collect a portfo-
lio comprising 5 complete ultrasound examinations,
which will be reviewed by two experts. Unsatisfactory
portfolios will be discussed with the sonographers in
order to improve quality. When at least 5 high quality
examinations of different patients have been collected,
the sonographer can participate in the study.
To ensure quality of the first trimester ultrasound, all
sonographers are asked to compile a new portfolio every
200 first trimester ultrasound scans.
Statistical issues
Sample size
The prevalence of anomalies in the high risk group is 5–
10% [38, 39]. The detection rate for fetal anomalies with
2D ultrasound in the first trimester lies between 18.2
and 71.8% [7]. As mentioned before, the detection rate
in a high risk population is estimated at 61%, and in a
low risk population at 63% for 2D ultrasonography [6,
8]. The detection rate for anomalies of the first trimester
3D VR ultrasound is 62.5% [20]. For second trimester
(18–22 weeks’ gestation) 2D ultrasound the detection
rate lies between 44.3 and 74.4% [40–42].
For sample size calculation with a superiority analysis
we assumed a 65% detection rate for a second trimester
2D ultrasound examination and a 70% detection rate for
the combined detection of first trimester 3D VR and sec-
ond trimester 2D ultrasound examination in a high risk
population. With an assumed prevalence of 7.5% and an
alpha-error of 0.05 with a desired power of 0.80, a total
group of N = 2800 is required.
Data-analysis
Data will be analyzed according to the intention-to-treat
principle. No interim analysis will be performed.
Statistical analysis will be performed using IBM SPSS
(SPSS Inc., Chicago, IL, USA) and R Studio (The R
Foundation for Statistical Computing). Descriptive statis-
tics will be used to describe the baseline characteristics
of both the control and intervention group (e.g. maternal
characteristics such as ethnicity, age, smoking status,
Body-Mass Index (BMI) and family history, pregnancy
characteristics such as parity and pregnancy outcome,
medication use such as antidepressants and antiepileptic
medication). Categorical data will be presented by num-
ber of participants (%) and numerical data by median
(interquartile range). These baseline characteristics will
be compared between the arms using Mann Whitney U-
test for continuous variables and chi-squared test for
categorical variables. When the expected count in 20%
or more of the cells of the cross table for the categorical
variables is 5 or lower or if any cell is empty an exact
test will be used instead. A significance level (alpha) of
0.05 will be used. No multiplicity correction will be
applied.
The economic analysis will be performed from the
societal perspective. The costs and quality of life will be
compared between the two diagnostic regimens.
Descriptive statistics will be used to describe the out-
comes of quality of life analysis (control arm versus
intervention arm).
Ultrasound is considered safe in pregnancy, therefore
a data monitoring committee is not required [43]. Yearly
reports will be sent to the ethics committee on the pro-
gress of the trial. When major modifications to the
protocol are made, all people involved will be informed.
Discussion
This is the first randomized controlled trial designed to
detect anomalies in the first trimester using 3D VR ultra-
sonography, with longitudinal follow-up in pregnancy.
One previous study has shown a high sensitivity for the
detection of structural anomalies in the first trimester
using 3D VR and a trend towards improved detection
rates [16]. 3D VR may especially improve the detection of
surface anomalies in the first trimester [20]. Timely detec-
tion of major congenital malformations will provide
women at risk with additional time to perform (genetic)
testing as well as more time to consider continuation or
termination of pregnancy. In current Dutch practice even
women from the high risk population are only offered a
second trimester anomaly scan. In the high risk group an
additional first trimester ultrasound examination may be
beneficial since there will be an increased prevalence of
anomalies. Furthermore, the absence of a major anomaly
following a first trimester 3D VR ultrasound examination
could offer earlier reassurance and reduce anxiety in preg-
nant women. Overall, we hypothesize this will improve
cost-effectiveness and patient quality of life.
This study has several strengths. The use of a stan-
dardized examination protocol will improve the detec-
tion of fetal anomalies. Recent studies have shown
increased detection rate of anomalies when a standard-
ized ultrasound protocol is used compared to a strategy
that consists of a global fetal survey [6]. Also, transvagi-
nal ultrasound or the combination of transvaginal and
transabdominal ultrasound may increase the detection of
anomalies in the first trimester compared to only using a
transabdominal approach. This is especially true in case
of maternal obesity. Detection of anomalies will be fur-
ther improved by the limited filtering of the ultrasound
data by the 3D VR system, which can enhance fetal sur-
face details and thus improve the examination of limbs
and face. This technique also provides recognizable and
identifiable ‘holograms’ for the future parents.
Some challenges remain. The introduction of a first
trimester ultrasound examination will necessitate an
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additional prenatal visit, as well as expertise and training
of staff. This might increase healthcare costs. This study
will add new understanding on maternal psychological
functioning throughout pregnancy in relation to prenatal
ultrasound. Ideally, we would use structured interviews.
However, due to the size of the study this was not a pos-
sibility. Instead we chose to use validated questionnaires
to investigate maternal stress and anxiety.
Some organ systems are not yet fully developed in the
first trimester or are too small to be visualized in detail.
As an example, one can state that it is not possible to
detect all or a large proportion of fetal cardiac and brain
anomalies in early pregnancy. Therefore, second trimes-
ter ultrasound examination cannot be omitted, and has
to be used in addition to first trimester ultrasound.
From a clinician’s point of view, the first trimester ultra-
sound should be studied regarding its additional value of
diagnostic performance. Rather than comparing first and
second trimester ultrasound examination, the perform-
ance should be based on the combination of first and sec-
ond trimester. We expect that first trimester detection will
show an improvement in the clinical care of participants
and lead to significant improvement in their quality of life.
Furthermore, a second trimester ultrasound examination
will show the development of a congenital anomaly over
time. Parents’ decision for continuation of the pregnancy
is likely to be affected by this. The second trimester ultra-
sound is indispensable, therefore we will study the com-
bined first and second trimester ultrasound examination
compared to the second trimester only.
This study will provide the highest level of evidence in
the evaluation of first trimester 3D VR ultrasonograhpy
in a high risk population concerning quality of life and
cost-effectiveness. Only with a randomized controlled
trial, like this study, the additional value of the 3D VR
desktop can be examined in terms of improved diagnos-
tic yield of regular first trimester 2D ultrasound and pa-
tients perspectives. If this new modality proves to be
cost-effective or shows to improve quality of life, it
should be offered in addition to the second trimester 2D
ultrasound examination. The wider implications of the
results will give policymakers and healthcare profes-
sionals an educated choice as whether to add first tri-
mester ultrasound for detection of congenital anomalies
in a high risk group as part of routine care.
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